Sanofi (SNY) has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer healthcare (CHC) business unit, Opella.Per the terms of the deal, Sanofi will remain a significant shareholder of Opella. In addition, the French investment bank, Bpifrance, is likely to hold a 2% stake and become a minority shareholder in Opella.The transaction is expected to close at the earliest in the second quarter o ...

Core Viewpoint - Sanofi and CD&R are entering exclusive negotiations for the potential sale of a 50% controlling stake in Opella, aiming to enhance Opella's position as a global leader in consumer healthcare while allowing Sanofi to focus on innovative biopharmaceuticals [1][3]. Company Overview - Opella, headquartered in France, employs over 11,000 people and operates in 100 countries with 13 manufacturing sites and four R&D centers. It is the third-largest player in the OTC and VMS market, serving over 500 million consumers globally [2]. - The company has a portfolio of well-known brands, including Allegra, Doliprane, and Dulcolax, and is positioned in a fast-growing industry driven by trends such as an aging population and increased health awareness [2]. Transaction Details - The enterprise value of Opella is approximately €16 billion, equating to about 14 times the estimated EBITDA for 2024. The transaction is binding and fully financed by CD&R [3]. - Sanofi will retain a significant minority stake in Opella, allowing it to benefit from future value creation [3]. - The transaction is expected to close in Q2 2025, subject to final agreements and regulatory approvals [3]. Strategic Implications - The partnership with CD&R is expected to leverage their expertise and resources to enhance Opella's market leadership and accelerate growth [4][6]. - Sanofi's focus will shift towards delivering innovative medicines and vaccines, while still supporting Opella's growth as an independent entity [5][6]. Financial Guidance - Sanofi has upgraded its 2024 business EPS guidance, now expecting low single-digit percentage growth at constant exchange rates, excluding Opella from its consolidated results [8]. - The anticipated cash payment from the transaction will align with Sanofi's capital allocation priorities, including shareholder returns and potential external growth opportunities [9].

Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines. Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity ...

US FLUBLOK label1 updated to incorporate new safety study in pregnant individuals New safety data involving more than 48,000 pregnant individuals published in American Journal of Obstetrics and Gynecology (AJOG) Global Reports Recombinant or inactivated flu vaccines are recommended by the U.S. Centers for Disease Control and Protection (CDC), Advisory Committee on Immunization Practices (ACIP) and American College of Obstetricians and Gynecologists (ACOG) for individuals who are or will become pregnant duri ...

BRIDGEWATER, N.J., Oct. 16, 2024 /PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase diversity in clinical studies. The investment over 10 years is aimed at strengthening Centers of Excellence in clinical study diversity at Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine. Funding will be used to hire clinical research staff, establish infrastructure such as ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics ...

Sanofi in discussions to sell a controlling stake in Opella Paris, October 11, 2024. Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. Should these discussions lead to a positive outcome, any agreement would be subject to the completion of the necessary social processes. Further updates on the potential separation of Opella will be provided in due course, when a decision is made. Head ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious Disease Society of America's IDWeek 2024 annual meeting in Los Angeles, California, from October 16-19, 2024. Thomas Triomphe Executive Vice President, Vaccines, Sanofi "The data featured at IDW ...

Sanofi (SNY) and partner Regeneron (REGN) announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the United States. The approved indication is as an add-on maintenance treatment of adults with inadequately controlled COPD and an eosinophilic phenotype. With this approval, Dupixent became the first biologic treatment approved for COPD in the United States. Dupixent was approved for treating COPD with raised blood eosi ...

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, generally known as "smoker's lung." Dupixent is the first biologic medicine approved in the U.S. to treat these patients. Also Read: Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease. The FDA approval is based on dat ...